Unleashing the immune system to fight cancer - Bristol Myers Squibb

Unleashing the immune system to fight cancer

A decade after a landmark approval, our research continues to uncover breakthroughs in immune checkpoint inhibition.

Bristol Myers Squibb has played a central role in some of the most significant developments in cancer treatment, including pioneering the first immune checkpoint inhibitor, Yervoy (ipilimumab), more than 10 years ago.

With Yervoy, researchers focused on the inhibition of a specific immune checkpoint, CTLA-4, to harness the body’s immune system to fight cancer. This novel approach launched a new class of cancer therapies, including our PD-1 inhibitor Opdivo (nivolumab). Building upon this expertise, we developed the first US Food and Drug Administration-approved combination of two immunotherapy agents–Opdivo plus Yervoy

Today, immune checkpoint inhibitors have improved how numerous cancers are treated, making long-term survival possible for more patients. As profound as these advances are, we know patients could benefit from more innovation. 

We continue to lead the field of immuno-oncology with ongoing research that includes relatlimab, our third distinct checkpoint inhibitor, blocking LAG-3.

Our deep understanding of tumor biology, the tumor microenvironment, and the immune system enables us to identify multiple tumor types where LAG-3 biology may be relevant. 

Looking ahead, we remain committed to developing the next wave of therapeutic innovations in pursuit of better, healthier lives for patients.

Patient Story

New hope–and new shoes

Read more >


More Science Stories


A legacy of pioneering advances in cardiovascular disease >
Transforming cells into cancer fighters >
The power of science, the power of AI >
Transforming patients' lives through science

The touch that transforms

2021 Annual Report


Visit bms.com to see how we're bringing a human touch to everything we do. 

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.